(Total Views: 594)
Posted On: 07/24/2020 11:25:45 AM
Post# of 154001
Thank you for that info CTMedic.
Lenzilumab looks interesting. I've been studying it, and I hope it is effective. Dr. Patterson said during his Dr. Been interview that elevated GM-CSF is only seen in 20-30% of patients, so its use may be limited.
Interestingly, its MOA appears to me (not an expert) to be one that would work well in concert with Leronlimab for patients who have elevated GM-CSF. It may be counteractive for those who do not have elevated GM-CSF, as it would supress the immune system
It would be interesting to see what the two of them together could do.
Lenzilumab looks interesting. I've been studying it, and I hope it is effective. Dr. Patterson said during his Dr. Been interview that elevated GM-CSF is only seen in 20-30% of patients, so its use may be limited.
Interestingly, its MOA appears to me (not an expert) to be one that would work well in concert with Leronlimab for patients who have elevated GM-CSF. It may be counteractive for those who do not have elevated GM-CSF, as it would supress the immune system
It would be interesting to see what the two of them together could do.
(0)
(0)
